The UK government has announced the establishment of the AI Biosecurity Lab (AIBL), a dedicated organisation intended to use advanced artificial intelligence (AI) to strengthen the detection and response to biological threats. The lab is backed by £100 million in government funding and up to £200 million in commitments from OpenAI and Anthropic, bringing the announced support for AIBL to up to £300 million.

Announced by the Cabinet Office on 24 October 2026, AIBL forms part of the UK’s National AI Biosecurity Initiative and builds on the country’s broader Biological Security Strategy. The lab will develop technical capabilities to help the UK and its international partners better understand, prevent, detect and respond to biological risks.

The subsequent Budget 2026, published on 28 October, confirmed a wider £165 million government investment in the National AI Biosecurity Initiative. This comprises the £100 million allocated to establishing AIBL and a further £65 million for bio-surveillance and the development of medical countermeasures.

OpenAI and Anthropic Commit Up to £200 Million

AIBL will launch with support from two major AI developers. OpenAI will provide £100 million in computing resources, model credits and trusted access to its most capable relevant models through the Rosalind Biodefense programme. Anthropic has committed up to £100 million in model credits, trusted model access and dedicated technical support.

Google DeepMind and UK-based AI life sciences company Basecamp Research will also collaborate with the lab. Google DeepMind scientists and biosecurity experts will participate in research collaborations, with the company looking to provide trusted access to frontier Gemini models and specialised scientific models. Basecamp Research will contribute access to its AI biology models, technical capabilities and expertise.

The announced company commitments are primarily in the form of computing resources, model credits, model access and technical support. They should therefore not be interpreted as £200 million in direct cash investment. The government also intends AIBL to receive philanthropic support, potentially providing an additional source of funding over time.

Early Detection and Medical Countermeasures

AIBL’s initial work will focus on two operational priorities:

• Earlier detection of biological threats: developing and deploying technical capabilities to identify emerging risks and improve the understanding of potential biological threats.
• Accelerated medical countermeasures: using AI to speed up the discovery, development and testing of vaccines, treatments and other medical countermeasures.

The Budget 2026 provides further detail on the wider initiative’s funding. Of the additional £65 million, £50.5 million is allocated to bio-surveillance, while £14.5 million represents an initial investment to support proof-of-concept development of novel medical countermeasures in partnership with the UK life sciences sector. These allocations sit alongside, rather than within, the £100 million allocated to establish AIBL.

The initiative reflects the UK government’s assessment that increasingly capable AI systems offer opportunities for scientific discovery and disease research while potentially lowering technical barriers to harmful biological activity.

Independent Organisation with Government Partnerships

AIBL is intended to operate as an independent, non-profit organisation, combining expertise in AI, life sciences and biosecurity. Its scientific advisory committee will draw on specialists from academia, industry and the third sector. Further details of the committee will be announced in due course.

The lab will work with key UK government bodies as part of the National AI Biosecurity Initiative, including:

• UK Health Security Agency (UKHSA);
• Animal and Plant Health Agency (APHA);
• Defence Science and Technology Laboratory (Dstl).

The Medicines and Healthcare products Regulatory Agency (MHRA) will also collaborate with AIBL to support preparedness for health emergencies and inform future regulation of AI-designed medicines.

The Budget confirms that the government intends to provide the £100 million for establishing AIBL between 2027–28 and 2029–30. The announcement therefore describes an organisation being established, rather than a fully operational laboratory with all its capabilities already in place.

The initiative is intended to strengthen the UK’s ability to respond to biological threats while supporting the development of AI-enabled scientific capabilities. For the pharmaceutical and biotechnology sectors, the planned collaboration with the MHRA is particularly relevant because it connects AI-enabled research and medical countermeasure development with regulatory preparedness for AI-designed medicines. The government announcement does not, however, set out new regulatory requirements or a specific approval pathway for such products.

The announcement was published by the UK Cabinet Office (introducing the AI Biosecurity Lab) on 24 October 2026. Further funding details were confirmed in Budget 2026, published by HM Treasury on 28 October 2026.